According to a new market report published by Lucintel, the future of the cancer/tumor profiling market looks promising with opportunities in the clinical and research applications. The cancer/tumor profiling market is expected to grow with a CAGR of 11% from 2019 to 2024. The major drivers for this market are growing demand for cancer profiling method by oncologists to diagnose cancers, rise in adoption of cancer biomarkers for tumor profiling, increasing utility of biomarkers in tumor profiling, increasing cancer patients across the globe, and growth in use of next-generation sequencing technique for cancer profiling.
In this market, immunoassays, hybridization, next-generation sequencing, and mass spectroscopy technologies are used to identify the cancer/tumor. Sequencing is the largest technology segment of the cancer/tumor profiling market.
Within the cancer/tumor profiling market, genetic biomarkers and protein biomarkers are the major biomarker type. Genetic biomarkers is the largest segment of the cancer/tumor profiling market.
North America will remain the largest region over the forecast period due to increasing investments for the discovery and development of biomarkers, growing demand for personalized therapeutics, rising adoption of advanced omics technologies for cancer research, and the increasing use of biomarkers for drug development.
Illumina, Qiagen N.V., Neogenomics Laboratories, HTG Molecular Diagnostics, Genomic Health, Caris Life Sciences, Helomics, Nanostring Technologies, Oxford Gene Technology, and Ribomed Biotechnologies are among the major manufacturers of cancer/tumor profiling devices.
Lucintel, a leading global strategic consulting and market research firm, has analyzed growth opportunities in the cancer/tumor profiling market by application, technology, cancer type, biomarker type, and region. Lucintel has prepared a comprehensive research report titled " Cancer/Tumor Profiling Market 2019-2024: Trends, Forecast, and Opportunity Analysis". The Lucintel report serves as a catalyst for growth strategy as it provides comprehensive data and analysis on trends, key drivers, and directions. The study includes a forecast for the cancer/tumor profiling market by application, technology, cancer type, biomarker type, and region as follows:
By Application [$M shipment analysis for 2013 – 2024]:
• Clinical Applications
• Research Applications
By Technology [$M shipment analysis for 2013 – 2024]:
• Immunoassays
• Hybridization
• Next-generation Sequencing
• Mass Spectroscopy
• Other Technologies
By Cancer Type [$M shipment analysis for 2013 – 2024]:
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Melanoma Cancer
• Other Cancer Types
By Biomarker Type [$M shipment analysis for 2013 – 2024]:
• Genetic Biomarkers
• Protein Biomarkers
• Other Biomarkers
By Region [$M shipment analysis for 2013 – 2024]:
• North America
o United States
o Canada
o Mexico
• Europe
o United Kingdom
o Germany
o France
o Italy
o Spain
• Asia-Pacific
o China
o India
o Japan
• ROW
o Brazil
A report of more than 150 pages will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or click on this link…… or [email protected].
About Lucintel
Lucintel, the premier global management consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, growth consulting, M&A, and due diligence services to executives and key decision-makers in a variety of industries. For further information, visit www.lucintel.com.
This report addresses the following key questions:
Q.1 What are some of the most promising potential, high-growth opportunities for the cancer/tumor profiling market by application (clinical applications and research applications), technology (immunoassays, hybridization, next-generation sequencing, mass spectroscopy, and other technologies (pyrosequencing and sanger sequencing), cancer type (breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma cancer, and other cancer types (non-hodgkin’s lymphoma, melanoma, leukemia, thyroid, bladder, and kidney)), biomarker type (genetic biomarkers, protein biomarkers, and other biomarkers), and region (North America, Europe, Asia-Pacific, and ROW)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 Which regions will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the cancer/tumor profiling market?
Q.5 What are the business risks and threats to the cancer/tumor profiling market?
Q.6 What are emerging trends in this cancer/tumor profiling market and the reasons behind them?
Q.7 What are some changing demands of customers in the cancer/tumor profiling market?
Q.8 What are the new developments in the cancer/tumor profiling market? Which companies are leading these developments?
Q.9 Who are the major players in this cancer/tumor profiling market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in this cancer/tumor profiling area and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M & A activities have taken place in the last 5 years in cancer/tumor profiling market?